OTTAWA, Feb. 28 /CNW/ - Liponex Inc. (TSX: LPX), a biopharmaceutical
company specializing in developing advanced products related to High Density
Lipoprotein (HDL), often called "good cholesterol," today announced that it
has received Health Canada approval to initiate a clinical trial in a patient
population using a new formulation of its lead pharmaceutical product, CRD5,
being developed for the treatment and prevention of heart disease.
